2024 年 4 月，该候选产品获得 CDE 临床试验默示许可。据新闻稿称，这是波睿达生物利用自主知识产权开发的 全球首个靶向 CD99 抗原的 CAR-T 细胞治疗候选产品，主要用于治疗≥18 周岁的复发/难治性 ...

Robert Negrin教授：问题核心在于如何利用调节性T细胞（regulatory T cells）于临床应用中。目前已有多种策略正在探索中。其中一个基本难题是，尚无能够特异性扩增调节性T细胞的药物。这类细胞在行为上与普通T细胞颇为相似，因此许多旨在激活和扩增调节性T细胞的药物也会同时扩增常规T细胞。例如，尽管白细胞介素-2（IL-2）是一种有吸引力的候选因子，但它也会影响其他免疫细胞群体。

Tumors are stressful places for cancer-fighting immune cells. Low oxygen, high acid levels, and other stressors put strain on ...

Immunologists from the Institute have been the first to uncover a role for a family of RNA binding proteins in the function ...

New research published in Immunity by researchers at the University of Pittsburgh found that, in mice, the toxic tumor ...

Scientists have uncovered a sweet twist in the body’s fight against cancer. Glucose, best known as the fuel that powers our ...

Indiana University School of Medicine scientists have developed a new method that shifts the behavior of immunosuppressive ...

Ocrevus rapidly depletes immune B-cells in people with MS, but ongoing treatment also leads to changes in immune T-cells, a ...

An engineered viral protein enhanced the anticancer function of T cells in mice, suggesting a new strategy to improve immunotherapy. Courtney and his team sought to exploit this property of TIP to ...